Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
3 Top Healthcare Stocks to Buy for November
10:00am, Friday, 04'th Nov 2022 The Motley Fool
Catalysts lie ahead for these promising stocks.
Is a Surprise Coming for Axsome (AXSM) This Earnings Season?
09:47am, Friday, 04'th Nov 2022
Axsome (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
08:41am, Friday, 04'th Nov 2022 Benzinga
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.
Acutus
Why Axsome Therapeutics Stock Is Soaring Today
03:49pm, Thursday, 03'rd Nov 2022 The Motley Fool
Some guessing is required to figure out what's behind today's big gain.
Robinhood, Under Armour, HubSpot And Some Other Big Stocks Moving Higher On Thursday
03:45pm, Thursday, 03'rd Nov 2022 Benzinga
U.S. stocks traded lower, with the Nasdaq Composite dropping more than 100 points on Thursday. Here are some big stocks recording gains in today’s session.
NerdWallet, Inc. (NASDAQ: NRDS) shares s
Why Axsome Therapeutics Stock Is Soaring Today
11:49am, Thursday, 03'rd Nov 2022
Some guessing is required to figure out what's behind today's big gain.
Axsome Therapeutics: All Eyes On Auvelity Launch
05:30pm, Wednesday, 02'nd Nov 2022
Shares of Axsome Therapeutics have posted a 30% gain so far in 2022. There's a sizeable niche and unmet need in the MDD market that Auvelity could address (novel MOA for patients who don't respond to
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
Axsome: Ramifications Of Recent Biotech Deals
02:30am, Sunday, 30'th Oct 2022
The macroeconomic factors create a highly favorable mergers and acquisition environment. Several interesting deals are being executed this month. As it's a strong buyers' market, you're likely to see
2 Top Biotech Stocks to Buy for the Long Haul
12:15pm, Friday, 28'th Oct 2022 The Motley Fool
Both drugmakers have outperformed the market in the past year.
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
11:00am, Thursday, 27'th Oct 2022 GlobeNewswire Inc.
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syst
Got $500? Buy These 2 Unstoppable Stocks
01:30pm, Wednesday, 26'th Oct 2022 The Motley Fool
Invest in these stocks if your priority is long-term growth.
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
11:00am, Friday, 21'st Oct 2022 GlobeNewswire Inc.
Axsome to host conference call and webcast on Monday, November 7, 2022 at 8:00 AM Eastern Time
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
07:00am, Friday, 21'st Oct 2022
Axsome to host conference call and webcast on Monday, November 7, 2022 at 8:00 AM Eastern Time
Here's Why You Should Consider Investing in JAZZ Stock Now
02:48pm, Monday, 17'th Oct 2022 Zacks Investment Research
JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.
